AdaptBox
AI-driven decision support for adaptive radiotherapy
Software · Cloud SaaSCompany source
Company profile
About Therapanacea SAS
TheraPanacea SAS is a medical technology company founded in 2017 that harnesses artificial intelligence to develop cutting-edge software for more efficient and precise cancer care. The company's flagship product, ART-Plan™, is a fully AI-powered, web-based solution for radiotherapy that optimizes every step of the treatment process from preparation to follow-up. The platform includes multiple modules: Annotate for automated contouring of over 250 organs-at-risk and lymph nodes, SmartFuse for high-precision image fusion, MR-Box for MR-only workflow with pseudo-CT generation, and AdaptBox for AI-driven adaptive radiotherapy decision support. TheraPanacea's solutions enable radiation oncology teams to save up to 93% of contouring time, delivering full-body expert-like contours in just 3 minutes. The company serves over 300 cancer centers across Europe and has supported treatment for more than 1.5 million patients. Beyond radiotherapy, TheraPanacea is developing ART-Omics™, an AI-powered radiomics platform for biomarker discovery to support pharmaceutical companies in drug development. The company's mission is to improve the quality of life of each patient by enabling healthcare providers to design smarter treatment plans, work more effectively, and reduce toxic side effects. TheraPanacea offers pioneering holistic approaches for cancer research and treatment based on multi-scale integration of medicine, information theory, data curation, and computational medicine.
Company description Therapanacea SAS official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Therapanacea SAS?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's Disease
- Brain tumors
- Breast cancer
- Cancer
- Gynecological cancers
- Head & Neck cancer
- Lung cancer
- Multiple Sclerosis
- Prostate cancer
Who it serves
- Cancer Centers
- Health Systems
- Pharmaceutical companies (for ART-Omics)
- Radiation Oncology Departments
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: CBCT, CT scanners, DICOM compliant devices, MRI scanners, PET-CT, Treatment Planning Systems (TPS).
Geographic context
MarketsEurope · France · International markets with FDA/TGA clearance
Company sourceOfficial website
Company milestones
Platform expansion
Finalist for INPI's Research Award (October 2025). Scientific presentations at ESTRO 2025 and ESTRO 2026. Development of new modules including SmartPlan (AI-powered treatment planning), TumorBox (brain tumor autosegmentation), and BrachyBox (brachytherapy delineation).
Partnerships
Recorded partners
- Industrial partners globally
- Leading cancer centers worldwide
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Annotate
AI-based automatic delineation for whole-body fast and highly-accurate contouring
Software · Cloud SaaSCompany source
ART-Omics™
AI-powered plug-n-play radiomics platform for biomarker discovery
Platform · Cloud SaaSCompany source
ART-Plan™
Fully AI-powered web-based solution for radiotherapy treatment planning
Platform · Cloud SaaSCompany source
BrachyBox
Fully automated delineation for brachytherapy cases
Software · Cloud SaaSCompany source
MR-Box
AI-powered MR-only workflow with pseudo-CT generation and annotation
Software · Cloud SaaSCompany source
SmartFuse
AI-powered software for high-precision rigid and deformable image fusion
Software · Cloud SaaSCompany source
SmartPlan
AI-powered treatment planning for radiotherapy
Software · Cloud SaaSCompany source
TumorBox
AI-powered precision for brain tumors autosegmentation
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
ART-Plan+ (v3.1.0)K253091 · 510k · Dec 23, 2025
ART-Plan+ (v.3.0.0)K242822 · 510k · Feb 25, 2025
ART-Plan (v.2.2.0)K234068 · 510k · Apr 22, 2024
ART-PlanK232479 · 510k · Dec 22, 2023
ART-PlanK230023 · 510k · Apr 19, 2023
ART-PLANK220813 · 510k · Jun 17, 2022
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
93% time saved in contouring
Automated organ-at-risk delineation
3 minutes for full-body delineation
Complete automated contouring workflow
250+ OARs and lymph nodes delineated automatically
Comprehensive anatomical coverage
1.5M+ patients treated yearly
Clinical adoption and impact
300+ centers using ART-Plan in Europe
Market penetration
Multiple European Cancer Centers
Automated contouring and radiotherapy treatment planning across multiple cancer centers
+300 centres using ART-Plan™ in Europe with +1.5M patients treated yearly
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Therapanacea SAS
Recent articles published on Therapanacea SAS's official website.
Innovations in Radiation Oncology: Harnessing AI for better patients outcomes [WEBINAR]
Read on Therapanacea SASClinically Relevant AI in Radiation Therapy [WEBINAR]
Read on Therapanacea SASTheraPanacea Partnering with LAP
Read on Therapanacea SASOur scientific work at ESTRO 2024
Read on Therapanacea SASUnlocking the Potential of AI Auto-Contouring in Radiotherapy at HELSE Bergen [WEBINAR]
Read on Therapanacea SAS07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.